Curriculum Vitae

Personal information

Petra Schlick

Work experience

October 2017 - present

Senior Quality Assessor
AGES/Austrian Medicines & Medical Devices Agency
Austria

Main Activities

CMC assessment (CP, DCP/MRP, national, Clinical Trial applications, quality defects) and Scientific Advice (EMA-SA, national) for Biologicals with main focus on vaccines (including Influenza), recombinant products, ATMPs and biosimilars. Profound expertise with the assessment of classical (inactivated, live-attenuated, recombinant, polysaccharide, conjugate) and novel (vector-based, mRNA-based) vaccine technologies.

Activities in EMA Working Parties/Groups: see below (Memberships)

May 2011 - October 2017

Quality Assessor
AGES/Austrian Medicines & Medical Devices Agency
Austria

Main Activities

CMC assessment (CP, DCP/MRP, national, Clinical Trial applications) and Scientific Advice (EMA-SA, national) for Biologicals with main focus on vaccines, recombinant products, ATMPs and biosimilars. Additional expertise with the assessment of plasma products.

Activities in EMA Working Parties/Groups (see below)

November 2009 - May 2011

Group Leader R&D
Intercell AG
Austria

Department Serology & Immune Assays

Main Activities

Project Lead / Management for several vaccine programmes, Grant acquisition and managment (EU and national), supervision of lab work, training of staff and PhD/Diploma Students, preparation of expert reports and regulatory submissions.

Main Research Areas

Vaccine R&D (diverse viral and bacterial targets):
Lead vaccine antigen characterization, in vitro bioassay development/optimization, animal models, mAb technology.

May 2004 - November 2009

Senior (Staff) Scientist R&D
Intercell AG
Austria

Department Models of Adjuvant-induced T-cell Immunity

Main Activities

Project Lead/Management, international collaborations, experimental work, supervision of staff and PhD/Diploma Students, preparation of expert reports and regulatory submissions.

Main Research Areas

Lead vaccine antigen characterization, animal models, T-cell immunity, immune assay development/optimization, identification/characterization of novel adjuvants.

Department Antigen Discovery

Main Activities

Project Lead/Management of several projects, international collaborations, core team member in several vaccine programmes (viral and bacterial targets), experimental work (incl. BSL3), supervision of staff and PhD/Diploma Students, preparation of expert reports and patent applications.

Main Research Areas

Vaccine antigen identification/characterization, genetic screening systems, surface display, gene expression assays, reverse genetics, recombinant DNA technology, protein expression/purification, serological assays, virological assays.

Education and training

April 2001 - July 2004

PhD (Microbiology)
University of Vienna
Austria

PhD Thesis: "Investigation of the HIV proteinase substrate specificity and inhibitor sensitivity using a bacterial genetic screen"

October 1995 - March 2001

Microbiology, Master of Science
Specialisation: Immunology/Cell Biology & Biochemistry
University of Vienna
Austria

Master Thesis: "Gezielte Mutagenese des aktiven Zentrums der Leader-Proteinase des Maul- und Klauenseuchevirus"

Additional information

Publications

Publications in Scientific Journals

Bernardo, L., Pavón, A., Hermida, L., Gil, L., Valdés, I., Cabezas, S., Linares, R., Alvarez, M., Silva, R., Guillén, G., Nagy, E., Schlick, P. & Guzmán, M.G. (2011). The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine 29, 4256-63.

Schmid, P., Selak, S., Keller, M., Luhan, B., Magyrics, Z., Seidel, S., Schlick, P., Reinisch, C., Lingnau, K., Nagy, E. & Grubeck_Loebenstein, B. (2011). Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age. Vaccine 29, 3982-9.

Schlick, P., Kofler, R.M., Schittl, B., Taucher, C., Nagy, E., Meinke, A. & Mandl, C.W. (2010). Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations. Vaccine 28, 5903-9.

Schlick, P., Taucher, C., Schittl, B., Tran, J.L., Kofler, R.M., Schueler, W., Von Gabain, A., Meinke, A. & Mandl, C.W. (2009). Helices α2 and α3 of West Nile virus capsid protein are dispensable for assembly of infectious virions. J. Virol. 83, 5581-91.

Schlick, P. & Skern, T. (2008). Investigating human immunodeficiency virus_1 proteinase specificity at positions P4 to P2 using a bacterial screening system. Anal Biochem. 377, 162-9.

Schrauf, S., Schlick, P., Skern, T. & Mandl, C.W. (2008). Functional analysis of potential carboxy_terminal cleavage sites of tick_borne encephalitis virus capsid protein. J Virol. 82, 2218-29.

Schlick, P. & Skern, T. (2002). Eukaryotic initiation factor 4GI is a poor substrate for HIV_1 proteinase. FEBS Lett. 529, 337-40.

Schlick, P., Kronovetr, J., Hampoelz, B. & Skern, T. (2002). Modulation of the electrostatic charge at the active site of Foot-and-mouth-disease virus leader proteinase, an unusual papain-like enzyme. Biochem J. 363, 493-501.

PhD & Master Thesis Schlick, P. (2004). Investigation of the HIV proteinase substrate specificity using a bacterial genetic screen. PhD Thesis, University of Vienna.

Schlick, P. (2001). Gezielte Mutagenese des aktiven Zentrums der Leader_proteinase des Maul_ und Klauenseuchevirus. Master Thesis, University of Vienna.

Projects

Memberships

EMA Biologics Working Party (BWP) Member (2023 - present)
Austrian representative of the BWP Adhoc Influenza Working Group (2017 - present)
EMA Vaccine Working Party (VWP) Observer (2013 - 2020)
Österreichische Gesellschaft für Vakzinologie

Other Relevant Information